Thursday, October 20, 2011

Tarceva Battles Lung Cancer in Some

(HealthDay News) -- New research finds that the targeted cancer drug Tarceva nearly triples the amount of time lung cancer patients survive without a recurrence and has fewer side effects than standard chemotherapy.

The authors of a study appearing in the July 21 online issue of The Lancet Oncology recommend using Tarceva (erlotinib) as a first-line treatment for patients with advanced non-small-cell lung cancer who have the particular gene mutation this drug targets.

Other experts agreed.

"This is a very important study [because] it shows that we can identify patients with a specific genetic marker and direct specific treatment toward them," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. Read more...

Immunice for Immune Support

No comments:

Advanced Body Cleansing Kit

Advanced Body Cleansing Kit

$147.75
[ learn more ]

Add to Cart

Advanced Body Cleansing Kit with Livatrex™, Oxy-Powder®, Latero-Flora™ and two bottles of ParaTrex®.